Profound Medical (NASDAQ:PROF – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Profound Medical and Sanara MedTech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
Profound Medical presently has a consensus target price of $11.50, suggesting a potential upside of 96.75%. Sanara MedTech has a consensus target price of $35.00, suggesting a potential downside of 0.02%. Given Profound Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than Sanara MedTech.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -171.57% | -63.03% | -51.24% |
| Sanara MedTech | -29.15% | 29.72% | 2.84% |
Valuation and Earnings
This table compares Profound Medical and Sanara MedTech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profound Medical | $16.10 million | 13.27 | -$42.57 million | ($0.98) | -5.96 |
| Sanara MedTech | $103.12 million | 3.12 | -$37.56 million | ($3.59) | -9.75 |
Sanara MedTech has higher revenue and earnings than Profound Medical. Sanara MedTech is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Profound Medical has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Insider and Institutional Ownership
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Profound Medical beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
